Section I. Introduction -- 1. Introduction: Classification, Terminology, Epidemiology and Etiology of Cutaneous Adverse Drug Reactions -- Section II. Pathomechanisms of Cutaneous Adverse Drug Reactions -- 2. Immunology of Cutaneous Adverse Drug Reactions -- 3. Pharmacogenomics and Cutaneous Adverse Drug Reactions -- 4 Viral Reactivation in Cutaneous Adverse Drug Reactions -- 5. Using Technology to Learn About Immunology of Cutaneous Adverse Drug Reactions -- Section III. Clinical Perspectives of Cutaneous Adverse Drug Reactions -- 6. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (Epithelial Necrolysis) -- 7. Drug Reaction with Eosinophilia and Systemic Symptoms -- 8. Acute Generalized Exanthematous Pustulosis -- 9. Urticarial Reactions to Drugs -- 10. Dermatological Adverse Events from Cancer Treatments -- 11. Cutaneous Adverse Drug Reactions in Pediatric Population -- 12. Cutaneous Drug Reactions in the Elderly -- 13. Cutaneous Adverse Drug Reactions in Human Immunodeficiency Virus Patients -- 14. Cutaneous Adverse Drug Reactions from Anti-Tuberculosis Treatment -- Section IV. Approach to the Patient with a Cutaneous Adverse Drug Reaction -- 15. Practical Approach to Diagnosis and Management of Cutaneous Adverse Drug Reactions -- 16. Histopathology of Severe Drug Eruptions -- 17. Evaluation of Drug Safety Literature: A Guide for the Practicing Dermatologist -- 18. In vitro and in vivo tests in Cutaneous Adverse Drug Reactions -- 19. Pharmacovigilance of Cutaneous Adverse Drug Reactions -- Section V. Epilogue -- 20. Future Directions and Unmet Research Needs in Cutaneous Adverse Drug Reactions -- 21. Atlas of Cutaneous Adverse Drug Reactions.

This resource guides prescribers, pharmacists, and regulators with an update on the recent expansion of basic and clinical knowledge that forms a framework for understanding cutaneous reactions. This understanding will lead, in turn, to better outcomes and decisions in treatment and management, both in the clinic and in the life cycle of drug development. The skin is a common target for adverse drug events and even mild rashes can be part of life-threatening syndromes. Patients and practitioners often face important decisions about therapy after a drug eruption, including treatment, cross-reactivity with future pharmaceuticals, genetic considerations and dealing with long-term sequelae after a reaction. An international team of experts and leaders in the field share their story and insights into the scientific details and relevant clinical context.